CORE Biomedicine
Developing the next generation of precision medicines by going beyond genomics.
$21MSeries A
Role not disclosedEV
Elikon Venture
Activity from announced rounds
Activity in this selectionnrw-venture-f5757e51
- Rounds participated in
- 3
- Confirmed lead rounds
- — 3 roles undisclosed
- New companies
- 3 First participation on record · 0 follow-on
- Funding in participating rounds
- $104M 3 disclosed · full round size, not this investor’s share
By stage
By primary sector
By country
Rounds
3 in this selectionFortitude Biomedicines
Develops antibody-based therapies for autoimmune diseases and cancer
$13MSeed
Role not disclosedOricell Therapeutics
Develops next-generation cell therapies for oncology and immunology
$70MSeries C1
Role not disclosed